Will Covaxin's Success Against COVID Variants Make Ocugen a Big Winner?

·2 min read

Ocugen (NASDAQ: OCGN) recently announced encouraging results from studies that indicated the potential for COVID-19 vaccine Covaxin to be effective against coronavirus variants. In this Motley Fool Live video, recorded on May 5, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Covaxin's success against emerging variants could help make Ocugen a big winner in the U.S. market.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting